Alterations in DNA Methylation in Peripheral Blood May Indicate Lymphoma Development in Primary Sjögren's Disease
Overview
This study identifies distinct DNA methylation changes in peripheral blood that precede lymphoma diagnosis in patients with primary Sjögren's disease (SjD).
Background
Primary Sjögren's disease is a systemic autoimmune condition associated with an elevated risk of lymphoma. Understanding the molecular mechanisms of lymphomagenesis in SjD is crucial for developing sensitive biomarkers for early identification of at-risk patients. This study explores the role of DNA methylation patterns in blood as potential indicators of lymphoma development.
Data Highlights
A total of 473 autosomal and one X-chromosomal differentially methylated positions (DMPs) were identified, with 87% being hypomethylated in SjD pre-lymphoma.
Key Findings
Six patients with SjD developed lymphoma ≥1 year after blood sampling.
Significant DMPs included Thymidine kinase 1 (TK1), FCER1G, and MDH2.
Functional enrichment analysis revealed pathways related to immune activation and leukocyte signaling.
Patients sampled pre-lymphoma showed reduced NK cell and increased monocyte proportions.
87% of identified DMPs were hypomethylated in the pre-lymphoma group.
Clinical Implications
Further research is needed to validate these findings.
Conclusion
Distinct DNA methylation changes precede lymphoma in SjD, affecting genes involved in immune regulation, cytotoxic function, and proliferation.
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
